Understanding Gastroparesis Risk with Ozempic: A Patient History Perspective

Latest update (2026-01)

FDA enforcement record (Ongoing): Presence of Particulate Matter: Hair was found in a prefilled syringe. [source]

From General Health Information to Specific Drug Risks

If you're taking Ozempic and experiencing persistent nausea, vomiting, or abdominal pain, you may be wondering if the medication could be contributing to gastroparesis. Decades of pharmacovigilance have established that certain drugs can slow gastric emptying, and newer GLP-1 receptor agonists are now under scrutiny for similar effects. This page examines the patient history, medication use, and chronological factors that may influence gastroparesis risk.

Find Out If You Qualify for Compensation →

Understanding Ozempic and Its Gastrointestinal Effects

Ozempic, a glucagon-like peptide-1 (GLP-1) receptor agonist, is prescribed for glycemic control in type 2 diabetes. However, its use has been associated with significant gastrointestinal adverse effects, including gastroparesis—a condition characterized by delayed gastric emptying without mechanical obstruction. This section examines the clinical presentation of gastroparesis, Ozempic's pharmacology and reported adverse effects, mechanistic pathways linking the drug to gastroparesis, adequacy of warnings, settlement considerations for affected patients, and the timeline between exposure and documented harm. Gastroparesis presents with symptoms such as nausea, vomiting, early satiety, postprandial fullness, bloating, and abdominal pain. Diagnosis typically involves gastric emptying scintigraphy showing delayed emptying. The condition can lead to malnutrition, weight loss, and impaired quality of life. In clinical trials, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic than placebo: placebo 15.3%, Ozempic 0.5 mg 32.7%, and Ozempic 1 mg 36.4% (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The majority of reports of nausea, vomiting, and/or diarrhea occurred during dose escalation (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). More patients receiving Ozempic 0.5 mg (3.1%) and Ozempic 1 mg (3.8%) discontinued treatment due to gastrointestinal adverse reactions than patients receiving placebo (0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). In a trial comparing Ozempic 1 mg and 2 mg, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic 2 mg (34.0%) vs Ozempic 1 mg (30.8%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Additional gastrointestinal adverse reactions with a frequency of less than 5% associated with Ozempic include dyspepsia (placebo 1.9%, 0.5 mg 3.5%, 1 mg 2.7%), eructation (0%, 2.7%, 1.1%), flatulence (0.8%, 0.4%, 1.5%), gastroesophageal reflux disease (0%, 1.9%, 1.5%), and gastritis (0.8%, 0.8%, 0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). These data indicate a dose-dependent increase in gastrointestinal side effects, which may include gastroparesis.

Mechanistic Link Between Ozempic and Gastroparesis

Mechanistically, GLP-1 receptor agonists like Ozempic slow gastric emptying by inhibiting gastric motility and increasing pyloric tone. This effect is mediated through vagal nerve pathways and direct action on GLP-1 receptors in the gastrointestinal tract. While this delayed gastric emptying is intended to improve postprandial glucose control, it can become pathological, leading to gastroparesis in susceptible individuals. The drug's label acknowledges gastrointestinal adverse reactions but does not explicitly list gastroparesis as a specific warning. The label includes a warning for hypersensitivity reactions, such as anaphylaxis and angioedema, but not for gastroparesis (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). This raises questions about the adequacy of warnings regarding Ozempic and gastroparesis.

Legal Considerations for Arizona Patients

For affected patients in Arizona, settlement considerations may involve proving that Ozempic caused or contributed to gastroparesis. Key factors include the timeline between exposure and documented harm. In clinical trials, gastrointestinal adverse reactions often occurred during dose escalation, suggesting that symptoms may emerge early in treatment (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). However, gastroparesis can develop after prolonged use, and the drug's long half-life (approximately one week) means that effects may persist after discontinuation. Patients who experienced severe gastrointestinal symptoms leading to hospitalization, malnutrition, or other complications may have stronger claims. Legal considerations include whether the manufacturer provided adequate warnings. The label reports gastrointestinal adverse reactions but does not specifically warn of gastroparesis. This omission could be argued as insufficient, especially given the drug's known mechanism of delaying gastric emptying. Settlement amounts may depend on the severity of harm, medical expenses, lost wages, and pain and suffering. In Arizona, statutes of limitations for product liability claims typically require filing within two years of discovering the injury.

Conclusion and Next Steps

In summary, Ozempic is associated with a high incidence of gastrointestinal adverse reactions, including those that may indicate gastroparesis. The drug's mechanism of delaying gastric emptying provides a plausible link to this condition. Warnings on the label do not specifically mention gastroparesis, which may affect legal claims. Patients in Arizona who developed gastroparesis after using Ozempic should consult with an attorney to evaluate their case, considering the timeline of exposure and documented harm.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the link between Ozempic and gastroparesis?

Ozempic, a GLP-1 receptor agonist, slows gastric emptying as part of its mechanism. In some individuals, this can become pathological, leading to gastroparesis—a condition of delayed gastric emptying without obstruction. Clinical trials show a dose-dependent increase in gastrointestinal adverse reactions, including nausea, vomiting, and dyspepsia, which may indicate gastroparesis (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166).

What legal options do Arizona patients have for Ozempic-related gastroparesis?

Arizona patients who developed gastroparesis after using Ozempic may pursue product liability claims. Key factors include proving causation, inadequate warnings (the label does not specifically mention gastroparesis), and the timeline of exposure. The statute of limitations in Arizona is typically two years from discovery of the injury. Consulting an attorney experienced in pharmaceutical litigation is recommended.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Ozempic exposure and a confirmed Gastroparesis diagnosis may request an independent eligibility review. [Begin Assessment]

References

DailyMed Ozempic Label

Find Out If You Qualify for Compensation

Statutes of limitations can limit the time you have to file a claim. A records screening is free and confidential.

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.